Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
2020
Stefania Cocco | Michela Piezzo | Alessandra Calabrese | Daniela Cianniello | Roberta Caputo | Vincenzo Di Lauro | Giuseppina Fusco | Germira di Gioia | Marina Licenziato | Michelino de Laurentiis
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still the main therapeutic approach for this subgroup of patients, therefore, progress in the treatment of TNBC remains an important challenge. Data derived from molecular technologies have identified TNBCs with different gene expression and mutation profiles that may help developing targeted therapies. So far, however, only a few of these have shown to improve the prognosis and outcomes of TNBC patients. Robust predictive biomarkers to accelerate clinical progress are needed. Herein, we review prognostic and predictive biomarkers in TNBC, discuss the current evidence supporting their use, and look at the future of this research field.
Mostrar más [+] Menos [-]Palabras clave de AGROVOC
Información bibliográfica
Este registro bibliográfico ha sido proporcionado por Directory of Open Access Journals
